| Identification | Back Directory | [Name]
NotoginsenosideFc | [CAS]
88122-52-5 | [Synonyms]
NotoginsenosideFc
-D-Glucopyranoside,(3a )-12-hydroxy-20- [(6-O-a -D-xylopyranosyl-(1f2)-O-a -Dglucopyranosyl) oxy]dammar-24-en-3-yl O-a
β-D-Glucopyranoside, (3β,12β)-12-hydroxy-20-[(6-O-β-D-xylopyranosyl-β-D-glucopyranosyl)oxy]dammar-24-en-3-yl O-β-D-xylopyranosyl-(1→2)-O-β-D-glucopyranosyl-(1→2)- | [Molecular Formula]
C58H98O26 | [MDL Number]
MFCD23379929 | [MOL File]
88122-52-5.mol | [Molecular Weight]
1211.38 |
| Chemical Properties | Back Directory | [density ]
1.47±0.1 g/cm3 (20 ºC 760 Torr) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [pka]
12.84±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Chemical Properties]
It is soluble in organic solvents such as methanol, ethanol, and DMSO, and is derived from Panax notoginseng. | [Uses]
Notoginsenoside Fc is a protopanaxadiol-type (PPD-type) saponin from Panax notoginseng, which has perfect anti-platelet aggregatory effect. | [in vivo]
Notoginsenoside Fc (3.5?mg/kg/day) accelerates reendothelialization and alleviates excessive neointimal formation following carotid artery injury in diabetic Sprague-Dawley rats (200±20?g) in vivo[1]. | [target]
PAFR | [storage]
Store at -20°C |
|
|